Le SIDA au Ghana (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.

Identifieur interne : 000038 ( PubMed/Curation ); précédent : 000037; suivant : 000039

Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.

Auteurs : Fred Stephen Sarfo [Ghana] ; Maame Anima Sarfo [Ghana] ; Betty Norman [Ghana] ; Richard Phillips [Ghana] ; George Bedu-Addo [Ghana] ; David Chadwick [Royaume-Uni]

Source :

RBID : pubmed:25340766

Descripteurs français

English descriptors

Abstract

Combination antiretroviral therapy (cART) has been widely available in Ghana since 2004. The aim of this cohort study was to assess the incidences of death, AIDS-defining events and non-AIDS defining events and associated risk factors amongst patients initiating cART in a large treatment centre. Clinical and laboratory data were extracted from clinic and hospital case notes for patients initiating cART between 2004 and 2010 and clinical events graded according to recognised definitions for AIDS, non-AIDS events (NADE) and death, with additional events not included in such definitions such as malaria also included. The cumulative incidence of events was calculated using Kaplan Meier analysis, and association of risk factors with events by Cox proportional hazards regression. Data were closed for analysis on 31st December, 2011 after a median follow-up of 30 months (range, 0-90 months). Amongst 4,039 patients starting cART at a median CD4 count of 133 cells/mm3, there were 324 (8%) confirmed deaths, with an event rate of 28.83 (95% CI 25.78-32.15) deaths per 1000-person follow-up years; the commonest established causes were pulmonary TB and gastroenteritis. There were 681 AIDS-defining events (60.60 [56.14-65.33] per 1000 person years) with pulmonary TB and chronic diarrhoea being the most frequent causes. Forty-one NADEs were recorded (3.64 [2.61-4.95] per 1000 person years), of which hepatic and cardiovascular events were most common. Other common events recorded outside these definitions included malaria (746 events) and respiratory tract infections (666 events). Overall 24% of patients were lost-to-follow-up. Alongside expected risk factors, stavudine use was associated with AIDS [adjusted HR of 1.08 (0.90-1.30)] and death (adjusted HR of 1.60 [1.21-2.11]). Whilst frequency of AIDS and deaths in this cohort were similar to those described in other sub-Saharan African cohorts, rates of NADEs were lower and far exceeded by events such as malaria and respiratory tract infections.

DOI: 10.1371/journal.pone.0111400
PubMed: 25340766

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:25340766

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.</title>
<author>
<name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Sarfo, Maame Anima" sort="Sarfo, Maame Anima" uniqKey="Sarfo M" first="Maame Anima" last="Sarfo">Maame Anima Sarfo</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Norman, Betty" sort="Norman, Betty" uniqKey="Norman B" first="Betty" last="Norman">Betty Norman</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Bedu Addo, George" sort="Bedu Addo, George" uniqKey="Bedu Addo G" first="George" last="Bedu-Addo">George Bedu-Addo</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Chadwick, David" sort="Chadwick, David" uniqKey="Chadwick D" first="David" last="Chadwick">David Chadwick</name>
<affiliation wicri:level="1">
<nlm:affiliation>The James Cook University Hospital, Middlesbrough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The James Cook University Hospital, Middlesbrough</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25340766</idno>
<idno type="pmid">25340766</idno>
<idno type="doi">10.1371/journal.pone.0111400</idno>
<idno type="wicri:Area/PubMed/Corpus">000038</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000038</idno>
<idno type="wicri:Area/PubMed/Curation">000038</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000038</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.</title>
<author>
<name sortKey="Sarfo, Fred Stephen" sort="Sarfo, Fred Stephen" uniqKey="Sarfo F" first="Fred Stephen" last="Sarfo">Fred Stephen Sarfo</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Sarfo, Maame Anima" sort="Sarfo, Maame Anima" uniqKey="Sarfo M" first="Maame Anima" last="Sarfo">Maame Anima Sarfo</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Norman, Betty" sort="Norman, Betty" uniqKey="Norman B" first="Betty" last="Norman">Betty Norman</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Bedu Addo, George" sort="Bedu Addo, George" uniqKey="Bedu Addo G" first="George" last="Bedu-Addo">George Bedu-Addo</name>
<affiliation wicri:level="1">
<nlm:affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Chadwick, David" sort="Chadwick, David" uniqKey="Chadwick D" first="David" last="Chadwick">David Chadwick</name>
<affiliation wicri:level="1">
<nlm:affiliation>The James Cook University Hospital, Middlesbrough, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The James Cook University Hospital, Middlesbrough</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint>
<date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Acquired Immunodeficiency Syndrome (drug therapy)</term>
<term>Acquired Immunodeficiency Syndrome (mortality)</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Anti-Retroviral Agents (therapeutic use)</term>
<term>Cohort Studies</term>
<term>Diarrhea (complications)</term>
<term>Female</term>
<term>Ghana (epidemiology)</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Infections (mortality)</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Proportional Hazards Models</term>
<term>Risk Factors</term>
<term>Stavudine (therapeutic use)</term>
<term>Treatment Outcome</term>
<term>Tuberculosis, Pulmonary (complications)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antirétroviraux (usage thérapeutique)</term>
<term>Diarrhée ()</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Ghana (épidémiologie)</term>
<term>Humains</term>
<term>Infections à VIH (mortalité)</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Jeune adulte</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Stavudine (usage thérapeutique)</term>
<term>Sujet âgé</term>
<term>Syndrome d'immunodéficience acquise (mortalité)</term>
<term>Syndrome d'immunodéficience acquise (traitement médicamenteux)</term>
<term>Tuberculose pulmonaire ()</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Anti-Retroviral Agents</term>
<term>Stavudine</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>Ghana</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Diarrhea</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Acquired Immunodeficiency Syndrome</term>
<term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en">
<term>Acquired Immunodeficiency Syndrome</term>
<term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr">
<term>Infections à VIH</term>
<term>Syndrome d'immunodéficience acquise</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Infections à VIH</term>
<term>Syndrome d'immunodéficience acquise</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Antirétroviraux</term>
<term>Stavudine</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Ghana</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Proportional Hazards Models</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Diarrhée</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Tuberculose pulmonaire</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>Ghana</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Combination antiretroviral therapy (cART) has been widely available in Ghana since 2004. The aim of this cohort study was to assess the incidences of death, AIDS-defining events and non-AIDS defining events and associated risk factors amongst patients initiating cART in a large treatment centre. Clinical and laboratory data were extracted from clinic and hospital case notes for patients initiating cART between 2004 and 2010 and clinical events graded according to recognised definitions for AIDS, non-AIDS events (NADE) and death, with additional events not included in such definitions such as malaria also included. The cumulative incidence of events was calculated using Kaplan Meier analysis, and association of risk factors with events by Cox proportional hazards regression. Data were closed for analysis on 31st December, 2011 after a median follow-up of 30 months (range, 0-90 months). Amongst 4,039 patients starting cART at a median CD4 count of 133 cells/mm3, there were 324 (8%) confirmed deaths, with an event rate of 28.83 (95% CI 25.78-32.15) deaths per 1000-person follow-up years; the commonest established causes were pulmonary TB and gastroenteritis. There were 681 AIDS-defining events (60.60 [56.14-65.33] per 1000 person years) with pulmonary TB and chronic diarrhoea being the most frequent causes. Forty-one NADEs were recorded (3.64 [2.61-4.95] per 1000 person years), of which hepatic and cardiovascular events were most common. Other common events recorded outside these definitions included malaria (746 events) and respiratory tract infections (666 events). Overall 24% of patients were lost-to-follow-up. Alongside expected risk factors, stavudine use was associated with AIDS [adjusted HR of 1.08 (0.90-1.30)] and death (adjusted HR of 1.60 [1.21-2.11]). Whilst frequency of AIDS and deaths in this cohort were similar to those described in other sub-Saharan African cohorts, rates of NADEs were lower and far exceeded by events such as malaria and respiratory tract infections.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">25340766</PMID>
<DateCreated>
<Year>2014</Year>
<Month>10</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>2016</Year>
<Month>01</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>09</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
<Journal>
<ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>9</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>e111400</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0111400</ELocationID>
<Abstract>
<AbstractText>Combination antiretroviral therapy (cART) has been widely available in Ghana since 2004. The aim of this cohort study was to assess the incidences of death, AIDS-defining events and non-AIDS defining events and associated risk factors amongst patients initiating cART in a large treatment centre. Clinical and laboratory data were extracted from clinic and hospital case notes for patients initiating cART between 2004 and 2010 and clinical events graded according to recognised definitions for AIDS, non-AIDS events (NADE) and death, with additional events not included in such definitions such as malaria also included. The cumulative incidence of events was calculated using Kaplan Meier analysis, and association of risk factors with events by Cox proportional hazards regression. Data were closed for analysis on 31st December, 2011 after a median follow-up of 30 months (range, 0-90 months). Amongst 4,039 patients starting cART at a median CD4 count of 133 cells/mm3, there were 324 (8%) confirmed deaths, with an event rate of 28.83 (95% CI 25.78-32.15) deaths per 1000-person follow-up years; the commonest established causes were pulmonary TB and gastroenteritis. There were 681 AIDS-defining events (60.60 [56.14-65.33] per 1000 person years) with pulmonary TB and chronic diarrhoea being the most frequent causes. Forty-one NADEs were recorded (3.64 [2.61-4.95] per 1000 person years), of which hepatic and cardiovascular events were most common. Other common events recorded outside these definitions included malaria (746 events) and respiratory tract infections (666 events). Overall 24% of patients were lost-to-follow-up. Alongside expected risk factors, stavudine use was associated with AIDS [adjusted HR of 1.08 (0.90-1.30)] and death (adjusted HR of 1.60 [1.21-2.11]). Whilst frequency of AIDS and deaths in this cohort were similar to those described in other sub-Saharan African cohorts, rates of NADEs were lower and far exceeded by events such as malaria and respiratory tract infections.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sarfo</LastName>
<ForeName>Fred Stephen</ForeName>
<Initials>FS</Initials>
<AffiliationInfo>
<Affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sarfo</LastName>
<ForeName>Maame Anima</ForeName>
<Initials>MA</Initials>
<AffiliationInfo>
<Affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Norman</LastName>
<ForeName>Betty</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Phillips</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bedu-Addo</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Komfo Anokye Teaching Hospital, Kumasi, Ghana; Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chadwick</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>The James Cook University Hospital, Middlesbrough, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MRC_MR/J01477X/1</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>10</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>BO9LE4QFZF</RegistryNumber>
<NameOfSubstance UI="D018119">Stavudine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Infect Dis. 2008 Apr 15;46(8):1271-81</RefSource>
<PMID Version="1">18444867</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):72-7</RefSource>
<PMID Version="1">17621240</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>PLoS Med. 2008 Oct 21;5(10):e203</RefSource>
<PMID Version="1">18942885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2008 Nov 30;22(18):2409-18</RefSource>
<PMID Version="1">19005264</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2009 Jan 2;23(1):41-50</RefSource>
<PMID Version="1">19050385</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMJ. 2009;338:a3172</RefSource>
<PMID Version="1">19171560</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Chin Med J (Engl). 2006 Oct 20;119(20):1677-82</RefSource>
<PMID Version="1">17097013</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Infect Dis. 2007 Feb 1;44(3):441-6</RefSource>
<PMID Version="1">17205456</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>HIV Med. 2007 Jan;8(1):46-54</RefSource>
<PMID Version="1">17305932</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Niger J Clin Pract. 2006 Dec;9(2):128-33</RefSource>
<PMID Version="1">17319344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):262-7</RefSource>
<PMID Version="1">17146376</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2007 Apr 26;356(17):1723-35</RefSource>
<PMID Version="1">17460226</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Infect Dis. 2007 Jun 15;44(12):1625-31</RefSource>
<PMID Version="1">17516408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):183-92</RefSource>
<PMID Version="1">17414934</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):304-10</RefSource>
<PMID Version="1">17414931</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Endocrinol Metab. 2007 Jul;92(7):2506-12</RefSource>
<PMID Version="1">17456578</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2010 Mar 13;24(5):697-706</RefSource>
<PMID Version="1">20177360</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2010 Mar 27;24(6):789-802</RefSource>
<PMID Version="1">20224307</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet Infect Dis. 2010 Apr;10(4):251-61</RefSource>
<PMID Version="1">20334848</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>HIV Med. 2010 Oct 1;11(9):554-64</RefSource>
<PMID Version="1">20345879</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70</RefSource>
<PMID Version="1">20700060</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2011 Jul 31;25(12):1471-9</RefSource>
<PMID Version="1">21572309</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2012 Mar 27;26(6):721-30</RefSource>
<PMID Version="1">22233655</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Infect. 2013 Jul;67(1):43-50</RefSource>
<PMID Version="1">23542785</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Antimicrob Chemother. 2014 Jan;69(1):254-61</RefSource>
<PMID Version="1">24003181</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Infect Dis. 2002 Jan 15;34(2):224-33</RefSource>
<PMID Version="1">11740712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Medicine (Baltimore). 2002 May;81(3):213-27</RefSource>
<PMID Version="1">11997718</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2002 Sep 1;31 Suppl 1:S16-23; discussion S24-5</RefSource>
<PMID Version="1">12218440</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2003 Jul 25;17(11):1675-82</RefSource>
<PMID Version="1">12853750</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2003 Jul;17 Suppl 3:S95-101</RefSource>
<PMID Version="1">14565615</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2004 Apr 9;18(6):887-95</RefSource>
<PMID Version="1">15060436</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2004 Aug 20;18(12):1615-27</RefSource>
<PMID Version="1">15280772</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Infect Dis. 2004 Nov 15;190(10):1860-8</RefSource>
<PMID Version="1">15499544</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19</RefSource>
<PMID Version="1">1361652</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):14-7</RefSource>
<PMID Version="1">15608518</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Infect Dis. 2005 Aug 1;41(3):376-85</RefSource>
<PMID Version="1">16007536</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):324-8</RefSource>
<PMID Version="1">16249707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):336-43</RefSource>
<PMID Version="1">16249709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Engl J Med. 2005 Dec 1;353(22):2325-34</RefSource>
<PMID Version="1">16319381</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Clin Infect Dis. 2006 Feb 1;42(3):418-27</RefSource>
<PMID Version="1">16392092</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Arch Intern Med. 2006 Jan 9;166(1):64-70</RefSource>
<PMID Version="1">16401812</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>HIV Med. 2006 Mar;7(2):99-104</RefSource>
<PMID Version="1">16420254</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2006 Mar 11;367(9513):817-24</RefSource>
<PMID Version="1">16530575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMC Infect Dis. 2006;6:59</RefSource>
<PMID Version="1">16551345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2006 Apr 22;367(9519):1335-42</RefSource>
<PMID Version="1">16631912</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>JAMA. 2006 Aug 16;296(7):782-93</RefSource>
<PMID Version="1">16905784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>AIDS. 2007 Jul;21 Suppl 3:S73-8</RefSource>
<PMID Version="1">17666964</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet. 2007 Aug 4;370(9585):407-13</RefSource>
<PMID Version="1">17659333</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Antivir Ther. 2007;12(6):889-97</RefSource>
<PMID Version="1">17926643</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Am Coll Cardiol. 2008 Aug 12;52(7):569-76</RefSource>
<PMID Version="1">18687253</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000163" MajorTopicYN="N">Acquired Immunodeficiency Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018119" MajorTopicYN="N">Stavudine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014397" MajorTopicYN="N">Tuberculosis, Pulmonary</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4207829</OtherID>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>04</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>10</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>10</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>10</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>1</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">25340766</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0111400</ArticleId>
<ArticleId IdType="pii">PONE-D-14-15796</ArticleId>
<ArticleId IdType="pmc">PMC4207829</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000038 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000038 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:25340766
   |texte=   Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:25340766" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaGhanaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024